ANI Pharmaceuticals (ANIP)

[Just the facts maam]

LD, with respect to Novitium, we know they are sitting on a patent for novel stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension.
which expires in 2041. It is also possible that they will be instrumental in driving Corti's growth through future 505(b)(2) filings for combination therapies using Corti. This is where Halozyme's Enhanze will likely be used to improve the administration delivery of combination therapy. This is an area where Dr. Tannenbaum can certainly give ANIP guidance. Likewise if, Libigel is approved under what ever name, they likely have the data to identify a number of drugs suitable for combination therapy with testosterone.

JMHO.